0001437749-26-010549
SEC filingPersistent operating losses widened to -$17.7M amid R&D investments and impairments, as LockeT sales growth from long-term hospital contracts and sales team expansion provided limited offset while free cash flow burn of -$8.3M signals acute liquidity pressure.
Catheter Precision reported a GAAP net loss of -$17.7M for FY 2025, driven by persistent operating losses as the Company invests in R&D for pipeline advancements like the KardioNav device while navigating impairments and non-operating charges. This reflects the challenges of a development-stage medical device firm where revenue generation lags behind expenditure needs, particularly as expected revenues remain inadequate to cover planned costs and liabilities.
Sales and marketing expenses rose due to full-year headcount from hires in Q2 2024, supporting the push for hospital adoption. These investments aim to build a sustainable revenue base but contribute to the negative operating cash flow of -$8.3M. Capital expenditures remained modest at $17K, yielding free cash flow of -$8.3M and underscoring limited internal funding capacity.
Liquidity remains a critical concern, with cash reserves insufficient to fund operations beyond the near term. The Company is evaluating capital raises and has adopted a holding company structure incorporating the FLYTE private aviation charter business, positioned for potential profitable growth to attract investors and offset medtech losses. Debt obligations and operational needs necessitate ongoing financing, with risks of spending reductions if external capital proves elusive. This going-concern dynamic emphasizes the balance between LockeT traction and broader cash sustainability.